Actinium Pharmaceuticals Inc at TD Cowen Inc Radiopharmaceutical Innovation Summit (Virtual) Transcript
Thanks, everybody, for staying with us today, and we're continuing with the TD Cowen Radiopharmaceutical Innovation Summit. My name is Boris Peaker. I'm one of the biotech analysts here. It's my pleasure to host Sandesh Seth, who is the CEO of Actinium Pharmaceuticals. And just before we get started, I just want to make two reminders. First, if you want to send me questions you can send directly to my e-mail at [email protected] or you can ask directly through the portal. And lastly, this is II voting season and TD Cowen, and I would appreciate your vote in biotech.
So with that, Sandesh, thanks for joining us.
Thanks for having me, Boris. Pleasure to be here.
So, one of the key questions that we often get on Actinium -- is if you could address the name of the company, really because your lead drug is -- uses iodine-131. So if you could say what -- but can you first of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
